Elizabeth Walsh, MD
Hematology & Oncology · Cambridge, MANPI 1962768812
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,556 of the $3,253 with a category attached, or 78.6%. E.r. Squibb & Sons, L.L.C. accounts for 78.6% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $2,556, 7.7 times the $331 reported in 2023.
Across 5 payments — averaging $650.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Intera Oncology, Inc$423
- Array Biopharma Inc$139
- AstraZeneca$135
Across 32 payments — averaging $6939.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$64K
- E.r. Squibb & Sons, L.L.C.$54K
- GSK$44K
- Sanofi US Services Inc.$41K
- Beigene, Ltd.$19K
What the payments were for
- Consulting fees$2,55679%
- Food & beverage$69721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $2,556 |
| Intera Oncology, Inc | 2 | $423 |
| Array Biopharma Inc | 1 | $139 |
| AstraZeneca | 1 | $135 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,253 in reported general payments places this provider in the 60th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 17 | $211 |
| Olanzapine | 11 | $151 |
| Prochlorperazine Maleate | 12 | $138 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cambridge
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Stephanie BernsteinWinchester$622K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Karl DsilvaPeabody$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.